INTRODUCTION
• Primary goal in treatment of cerebral AVMs is to reduce risk of hemorrhage
• Seizures are the second most common presenting symptom of cerebral AVMs
INTRODUCTION (CONT.)
• Surgery, endovascular embolization, and radiosurgery are all treatment options available at the University of Alabama at Birmingham
• Research question: for patients with cerebral AVMs in whom seizures were the presenting symptom, does radiosurgical treatment (the least invasive of the modalities) afford an overall improvement in quantity of seizures (and quality of life)?
METHODS
• Collected retrospective chart data on 204 consecutive patients with cerebral AVMs treated with Leksell Gamma Knife at UAB between January 1991 and June 2012
• Of these, 78 patients (38.2%) had seizures as a presenting symptom
• Patients received ~17.5 Gy (range 17-22) to the 50% isodose line
• Standard of care: 1-month clinic follow-up, 3-month follow-up MRI, and surveillance MRIs every 6-12 months for 3 years.
• At 3 years post-treatment, patients standardly undergo either CTA or digital subtraction angiography to assess response to treatment
RESULTS
• At last clinical follow-up (mean 37.1 ± 38.3 months, range 0.9-246.6 months), 63 (80.8%) of the 78 patients were classified as Class I on the Engel Epilepsy Surgery Outcome Scale, 8 (10.3%) as Class II, 3 (3.8%) as Class III, and 4 (5.1%) as Class IV.
• Multivariate analysis did not demonstrate any significant correlation between the likelihood of an Engel Class I at last follow-up and patient demographics, comorbidities, AVM characteristics, history of operative intervention, pre-or posttreatment hemorrhage, or radiographic degree of resolution
RESULTS (CONT.)
• All adverse events potentially related to the AVM or radiosurgical procedure were included
• Fifty-four complications were encountered in 45 patients (22.1%):
• Headache in 10 patients
• Hemorrhage in 13
• Neurological deficit (i.e., hemiparesis, decreased sensation, visual field cut) without hemorrhage in 10 patients
• Symptomatic cerebral edema in 6
• New-onset seizure in 5
• Radiation necrosis in 3
• Dysphasia in 2
• Ventricular shunt in 2
• Syncope in 1
• Memory loss in 1
• Alopecia in 1
• Ten patients (4.9%) eventually underwent craniotomy for AVM resection with or without hematoma evacuation.
DISCUSSION
• This study found a clear tendency toward seizure improvement in AVM patients following treatment with SRS, with 81% of patients presenting with seizure, attaining Class I on the Engel Epilepsy Surgery Outcome Scale
• There is significant variation in the literature with regard to the exact rates of improvement, but the majority of studies have indicated good long-term seizure outcome in AVM patients who undergo SRS
DISCUSSION (CONT.)
• The mechanism by which SRS leads to a reduction in seizures has not been fully elucidated
• Improved cerebral hemodynamics following radiosurgical obliteration may contribute to control of seizures and other adverse symptoms
• Animal models studies have found that exposure to ionizing radiation produces alterations in synaptic transmission and biochemical/structural changes that reduce susceptibility to seizures
• There are conflicting data in the literature with regard to whether treatment modality has a significant effect on seizure outcomes in AVM patients
• Recent retrospective study performed at Johns Hopkins suggested that seizure control is more effective with surgical resection than radiosurgical ablation of AVMs, but that de novo seizures are more likely following surgical resection than radiosurgery
• Prospective Scottish Intracranial Vascular Malformation Study (SIVMS) demonstrated the lack of a statistically significant difference in seizure outcomes between the different treatment modalities, but also showed no statistical difference in the incidence of de novo or recurrent seizures over a 5-year period between AVM patients who received therapy and those managed conservatively
LIMITATIONS/FUTURE DIRECTIONS
• Single-center study
• Retrospective data collection
• Future studies could include multi-center prospective data collection and comparison of seizure outcomes between the different treatment modalities at US medical centers
